Regeneration of critical-sized defects, in a goat model, using a dextrin-based hydrogel associated with granular synthetic bone substitute

The development of injectable bone substitutes (IBS) have obtained great importance in the bone regeneration field, as a strategy to reach hardly accessible defects using minimally invasive techniques and able to fit to irregular topographies. In this scenario, the association of injectable hydrogel...

Full description

Bibliographic Details
Main Author: Pereira, Isabel Sofia Melo (author)
Other Authors: Pereira, José Eduardo (author), Maltez, Luís (author), Rodrigues, Alexandra (author), Rodrigues, Catarina (author), Oliveira, Manuela (author), Silva, Dina M. (author), Caseiro, Ana Rita (author), Prada, Justina (author), Maurício, Ana Colette (author), Santos, José Domingos (author), Gama, F. M. (author)
Format: article
Language:eng
Published: 2021
Subjects:
Online Access:http://hdl.handle.net/1822/70789
Country:Portugal
Oai:oai:repositorium.sdum.uminho.pt:1822/70789
Description
Summary:The development of injectable bone substitutes (IBS) have obtained great importance in the bone regeneration field, as a strategy to reach hardly accessible defects using minimally invasive techniques and able to fit to irregular topographies. In this scenario, the association of injectable hydrogels and bone graft granules is emerging as a well-established trend. Particularly, in situ forming hydrogels have arisen as a new IBS generation. An in situ forming and injectable dextrin-based hydrogel (HG) was developed, aiming to act as a carrier of granular bone substitutes and bioactive agents. In this work, the HG was associated to a granular bone substitute (Bonelike®) and implanted in goat critical-sized calvarial defects (14mm) for 3, 6 and 12weeks. The results showed that HG improved the handling properties of the Bonelike® granules and did not affect its osteoconductive features, neither impairing the bone regeneration process. Human multipotent mesenchymal stromal cells from the umbilical cord, extracellular matrix hydrolysates and the pro-angiogenic peptide LLKKK18 were also combined with the IBS. These bioactive agents did not enhance the new bone formation significantly under the conditions tested, according to micro-computed tomography and histological analysis.